Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

668 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP Zaire ebolavirus Vaccine to Inform Marburg Virus and Sudan ebolavirus Vaccines.
Coller BG, Lapps W Jr, Yunus M, Bruno S, Eichberg MJ, Lee AW, Liu K, Drury R, Millogo J, Macareo LR, Armstrong TH, Blue JT, Isopi LA, Hughes M, VanRheenen SM, Deutsch J, Tell JG, Dubey SA. Coller BG, et al. Among authors: lee aw. Vaccines (Basel). 2022 Sep 1;10(9):1446. doi: 10.3390/vaccines10091446. Vaccines (Basel). 2022. PMID: 36146524 Free PMC article. Review.
A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults.
Russell KL, Rupp RE, Morales-Ramirez JO, Diaz-Perez C, Andrews CP, Lee AW, Finn TS, Cox KS, Falk Russell A, Schaller MM, Martin JC, Hyatt DM, Gozlan-Kelner S, Bili A, Coller BG. Russell KL, et al. Among authors: lee aw. Hum Vaccin Immunother. 2022 Nov 30;18(5):2046960. doi: 10.1080/21645515.2022.2046960. Epub 2022 Mar 15. Hum Vaccin Immunother. 2022. PMID: 35290152 Free PMC article. Clinical Trial.
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
Lee AW, Liu K, Lhomme E, Blie J, McCullough J, Onorato MT, Connor L, Simon JK, Dubey S, VanRheenen S, Deutsch J, Owens A, Morgan A, Welebob C, Hyatt D, Nair S, Hamzé B, Guindo O, Sow SO, Beavogui AH, Leigh B, Samai M, Akoo P, Serry-Bangura A, Fleck S, Secka F, Lowe B, Watson-Jones D, Roy C, Hensley LE, Kieh M, Coller BG; PREVAC Study Team. Lee AW, et al. Clin Infect Dis. 2024 Apr 10;78(4):870-879. doi: 10.1093/cid/ciad693. Clin Infect Dis. 2024. PMID: 37967326 Free PMC article. Clinical Trial.
A double-blind, randomized, multicenter, controlled study to evaluate the immunogenicity, safety, and tolerability of varicella vaccine (VARIVAX™) passage extension 34 (PE34) process administered concomitantly with measles, mumps, and rubella vaccine (M-M-R™ II).
Silas PE, Zissman EN, Gardner J, Helian S, Lee AW, Platt HL. Silas PE, et al. Among authors: lee aw. Hum Vaccin Immunother. 2020 Nov 1;16(11):2634-2640. doi: 10.1080/21645515.2020.1743122. Epub 2020 May 19. Hum Vaccin Immunother. 2020. PMID: 32429738 Free PMC article. Clinical Trial.
668 results